Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naptumomab Estafenatox + Pembrolizumab in Urothelial Cancer
NCT05894447Phase 1Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naptumomab estafenatox in urothelial carcinoma (UC), sponsored by Weill Cornell Medicine. Primary endpoint: Recommended Phase 2 Dose at Day 21. Planned start Nov 2023; status: withdrawn.
02
Drugs
naptumomab estafenatox
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05894447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894447.